Please login to the form below

Not currently logged in
Email:
Password:

Amylin's Byetta may have cancer risk

Amylin Pharmaceuticals and Eli Lilly's long-acting Byetta may be tied to an increased cancer risk, a US agency drug reviewer said

Amylin Pharmaceuticals and Eli Lilly's long-acting Byetta (exenatide) may be tied to an increased cancer risk, a US agency drug reviewer said, raising concerns that the diabetes drug may need strict warnings.

The memo, dated January 25, was posted on the Food and Drug Administration's (FDA) website on April 9. It said that Byetta could give a "false sense of security" to physicians and patients about the drug's links to cancer.

Curtis Rosebraugh, head of the FDA's Office of Drug Evaluation II, noted that data from rodent studies on intravenous dosing of Byetta and Bydureon (the weekly version of the drug) "seem to give a similar signal" as seen with Novo Nordisk's Victoza (liraglutide).

Rosebraugh said: "Our internal data indicates that the preclinical findings are not unique to liraglutide but will probably extend to all" similar long-acting GLP-1 analogues, a class of medicines amongst extended-release diabetes drugs which includes Victoza and Byetta. In December, the FDA asked Eli Lilly and Amylin to conduct more safety studies on Byetta. No new studies were ordered for Bydureon.

Victoza was approved in January after 10 months of delay because of safety concerns. During the review, the FDA said thyroid tumours may be common with all extended-release diabetes drugs. The new memo is a the first indication that Byetta will carry the same boxed warning – the agency's strictest warning.

Analysts have said that the boxed warning may dissuade some GPs from prescribing the drug. This may make it harder for GLP-1 analogues to achieve the growth assumed by some investors.

12th April 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Valid Insight

Valid Insight is an award-winning pharmaceutical global market access consultancy....

Latest intelligence

DEMAND DIVERSITY REPORT 02: Why is the LGBTQ+ community facing poorer health outcomes due to COVID-19?
We’re all aware that clinical trials have been discussed more widely since the COVID-19 pandemic. While that’s a great thing for raising awareness of clinical trials in general, it’s also...
CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...

Infographics